BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Index insights
Special reports
Infographics: Dynamic digital data analysis
Trump administration impacts
Biopharma M&A scorecard
BioWorld 2024 review
BioWorld MedTech 2024 review
BioWorld Science 2024 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Coronavirus
More reports can be found here
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe
BioWorld - Monday, July 14, 2025
See today's BioWorld
Home
» South Korea's GI Innovation secures $31M in series B round for microbiome work
To read the full story,
subscribe
or
sign in
.
South Korea's GI Innovation secures $31M in series B round for microbiome work
Oct. 1, 2019
By
Jihyun Kim
HONG KONG – GI Innovation Inc., a microbiome combination drug developer based in Seoul, South Korea, has recently issued fully paid convertible preferred stock (CPS) worth KRW37.5 billion (US$31 million) for a series B investment.
BioWorld
Financings